Gefitinib: A review of its use in the management of advanced non-small-cell lung cancer

Drugs

Volumn 64, Issue 21, 2004, Pages 2475-2492

  Frampton, James E ^a   Easthope, Stephanie E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GEMCITABINE; LOPERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; STAT PROTEIN;

ACNE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEPHARITIS; BLOOD TOXICITY; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRY SKIN; EMBASE; EYE TOXICITY; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MEDLINE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OUTCOMES RESEARCH; PRURITUS; RASH; REVIEW; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA, NON-SMALL-CELL LUNG; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUALITY OF LIFE; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 8344230861     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464210-00008     Document Type: Review

References (88)

1. Herbst R, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003 Dec 1; 9: 5813-24
2. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004 Jul 28; 292 (4): 470-84
3. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55-61
4. Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved? JAMA 2004 Jul 28; 292 (4): 499-500
5. Lynch T. Clinical benefit in NSCLC: the evidence for gefitinib (Iressa, ZD1839). EJC Supplements 2003 Oct; 1 (8): 17-22
6. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003 Oct 2; 22 (43): 6629-38
7. Cappuzzo F, Bartolini S, Crino L. Emerging drugs for non-small cell lung cancer. Expert Opin Emerg Drugs 2003 May; 8 (1): 179-92
8. El-Reyes BF, LoRusso PM. Targetting the epidermal growth factor receptor. Br J Cancer 2004; 91: 418-24
9. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001 Sep 15; 19 (18 Suppl.): 32S-40S
10. Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003; 30 (1 Suppl. 1): 49-55
11. Janas M, Bailey LR, Schmidt N, et al. Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment, [abstract no. 7024] 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 619
12. Culy CR, Faulds D. Gefitinib. Drugs 2002; 62 (15): 2237-48
13. Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004; 29: 95-103
14. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60 Suppl. 1: 33-40; discussion 41-2
15. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002 Oct 15; 62 (20): 5749-54
16. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 [abstract no. LB-170]. 94th Annual Meeting of the American Association for Cancer Research; 2003 Jul 11-14: Washington, DC, 1362
17. Bailey LR, Janas M, Schmidt K, et al. Evaluation of epidermal growth factor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy [abstract no. 7013]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 618
18. Belani CP. ASCO conference highlights: EGFR mutations take centre stage. Signal 2004; 5 (2): 18-22
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304: 1497-500
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004; 350 (21): 2129-39
21. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96 (15): 1133-41
22. Pao W, Miller VA, Venkatraman E, et al. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 2004; 96 (15): 1117-9
23. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004 Aug 20; 305 (5687): 1163-7
24. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002 May 1; 20 (9): 2240-50
25. AstraZeneca. IRESSA™. International prescribing information. Macclesfield: AstraZeneca, 2004 Jan 15
26. McKillop D, Stephens TC, Partridge EA, et al. The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumours [abstract no. A100]. Clin Cancer Res 2003; 9 (16 Pt 2): 6093
27. Data on file. AstraZeneca, 2004
28. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 Jun 15; 21 (12): 2237-46
29. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 Oct 22; 290 (16): 2149-58
30. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84
31. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94
32. Wolf M, Farina-Sisofo D, Grous J, et al. Statistical analysis of survival in patients with advanced non-small-cell lung cancer treated with gefitinib (Iressa, ZD1839) in an expanded access program: preliminary results. EJC Supplements 2003 Sep; 1 (5): 248 plus poster presented at the European Respiratory Society 13th Annual Congress, Vienna; 2003 Sept 27-Oct 1
33. Ochs J, Grous JJ, Warner KL, et al. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access program (EAP) [abstract no. 7060]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 628
34. Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004 Jan 12; 90(1): 82-6
35. Santoro A, Cavina R, Latteri F, et al. Activity of a specific inhibitor, gefitinib (Iressa TM, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 2004 Jan; 15(1): 33-7
36. Haringhuizen A, van Tinteren H, Vaessen HFR, et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004 May; 15 (5): 786-92
37. Spaeth D, Deplanque G, Favrot N, et al. Gefitinib in heavily pretreated non small cell lung cancer: results of the expanded access program in Eastern France [abstract no. 7323]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 693
38. Parton M., Maisey N, Banerjee S, et al. Gefitinib in patients with non-small-cell lung cancer (NSCLC): The Royal Marsden Experience [abstract no. 7099]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 638
39. Forsythe B, Faulkner K. Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience [abstract no. P327]. Eur Respir J 2003 Sep; 22 Suppl. 45: 32s plus poster presented at the European Respiratory Society 13th Annual Congress, Vienna; 2003 Sept 27-Oct 1
40. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-53
41. Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the Functional Assessment of Cancer Therapy-Lung scale. Semin Oncol 2003; 30 (1 Suppl. 1): 39-48
42. Natale RB, Skarin A, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. 38th Proc Am Soc Clin Oncol 2002 May; 21 (Pt 1 of 2): 292 plus poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18; Orlando
43. Gatzemeier U, Douillard JY, Kris M, et al. Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib [abstract no. 52]. EJC Supplements 2003 Sep; 1 (5): 20
44. Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. EJC Supplements 2003; 1 (8): 9-15
45. Kelly K. The benefits of achieving stable disease in advanced lung cancer. Oncology 2003 Jul; 17 (7): 957-63
46. Smit F, Douillard JY, Kris M, et al. Gefitinib (Iressa, ZD1839) improves disease-related symptoms in NSCLC. Eur Respir J Suppl 2003 Sep; 22 Suppl. 45: 29
47. Herbst R, Natale R, Giaccone G, et al. ZD1839 improves disease-related symptoms and quality of life of patients with locally advanced or metastatic non-small-cell lung cancer in two randomized, double-blind studies (IDEAL-1 and IDEAL-2) [abstract no. P367]. Chest 2002 Oct; 122 Suppl.: 166S
48. Douillard JY, Cella D, Natale RB, et al. Clinically meaningful improvement in disease-related symptoms by gefitinib (Iressa, ZD1839) in patients with advanced non-small-cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. EJC Supplements 2003 Sep; 1 (5): 276-7
49. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16
50. Herbst RS, Giaccone G, Schiller J, et al. Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy for advanced non-small-cell lung cancer [abstract no. 2523]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago, 627
51. West H, Franklin WA, Gumerlock PH. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group Study (SWOG) S0126 [abstract no. 7014]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 618
52. Dickson NR, Hainsworth JD, Spigel DR, et al. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial [abstract no. 7086 plus presentation]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 634
53. Kommareddy A, Coplin M, Gao F, et al. Single-agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 2004 Aug; 45 (2): 221-5
54. Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 43: 317-22
55. Niho S, Kubota K, Goto K, et al. First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study [abstract no. 7059]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 628
56. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clinical Lung Cancer 2003; 4 (6): 366-9
57. Tullo AB, Esmaelli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in phase I and II clinical trials. Eye. In press
58. van Zandwijk N. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer 2003; 89 Suppl. 2: S9-S14
59. Liu CY, Seen S. Gefitinib therapy for advanced non-small-cell lung cancer. Ann Pharmacother 2003; 37 (11): 1644-53
60. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targetted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004 Jul 15; 10 (14): 4607-13
61. Cersosimo RJ. Lung cancer: a review. Am J Health-Syst Pharm 2002 Apr 1; 59: 611-42
62. Fossella FV. Docetaxel for previously treated non-small-cell lung cancer. Oncology (Huntingt) 2002 Jun; 16 (6 Suppl. 6): 45-51
63. Hanna HL. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. Clin Lung Cancer 2004 Apr; (5 Suppl. 2): S75-9
64. Cersosimo RJ. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. Am J Health-Syst Pharm 2004 May 1; 61: 889-98
65. Harper P. Symptoms and quality of life: important patient outcomes? EJC Supplements 2003; 1 (8): 23-8
66. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8 (4): 303-6
67. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004 Jan 15; 22 (2): 330-53
68. National Comprehensive Cancer Network. Clinical practice guidelines in oncology v.1.2004 [online]. Available from URL: http://www.nccn.org [Accessed 2004 Aug 31]
69. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004; 90: 566-72
70. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract no. 7022]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 21
71. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract no. 7010]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 617
72. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer [abstract no. 7011]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 617
73. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004 Mar 1; 22 (5): 759-61
74. Stahel R, Rossi A, Petruzelka L, et al. Lessons from the 'Iressa' expanded access programme: gefitinib in special patient populations. Br J Cancer 2003; 89 Suppl. 2: S19-23
75. Zinner R, Govindan R, Wozniak AJ, et al. Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP) [abstract no. 7082]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 633
76. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003 Nov 17; 89 (10): 1827-9
77. Copin M, Kommareddy A, Behnken D, et al. Gefitinib in elderly patients with non-small cell lung cancer [abstract no. 3048 plus poster]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago, 758
78. Kelly K, Averbuch S. Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol 2004; 31 (1 Suppl. 1): 93-9
79. Manegold C. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recent results and further strategies. Adv Exp Med Biol 2003; 532: 247-52
80. Manegold C, Gatzemeier U, Smith R, et al. Final data from a pilot trial of gefitinib (Iressa, ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer: safety and pharmacokinetics. Onkologie 2003; 26 Suppl. 5: 141
81. Rixe O, Lemarie E, Chomy F, et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC): clinical results and biological monitoring [abstract no. 2659]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago, 661
82. Williams CC, Haura EB, Antonia SJ, et al. Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 698
83. Scagliotti GV, Rossi A, Novello S, et al. Gefitinib ('Iressa', ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small-cell lung cancer [abstract no. 7081]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 633
84. Rischin D, Burmeister B, Mitchell P, et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer [abstract no. 7077]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 632
85. O'Byrne K, Clark L, Dunlop D, et al. Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC) [abstract no. 7101]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 638
86. Gadgeel SM, Shehadeh NJ, Ruckdeschel JC, et al. Gefitinib (Iressa) and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC) [abstract no. 7094]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 636
87. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004 Mar 15; 22 (6): 1103-9
88. Seto T, Yamamoto N. Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey [abstract no. 7064]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, 629